Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GPC3-CAR-T cells in hepatocellular carcinoma
NCT04506983Phase 1Suspended
- Sponsor
- Beijing Tsinghua Changgung Hospital
- Start
- Jun 2022
- Primary completion
- Jun 2023
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of GPC3-CART cells in hepatocellular carcinoma (HCC), sponsored by Beijing Tsinghua Changgung Hospital. Primary endpoint: Adverse Events at 12 months. Started Jun 2022; status: suspended.
02
Drugs
GPC3-CART cells
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT04506983.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04506983.